Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press16610.17650/2313-805X-2018-5-3-59-64RESEARCH ARTICLESЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИCytotoxic cationic peptides as а ligands for receptor nucleolinЦитотоксичные катионные пептиды как лиганды рецепторного нуклеолинаhttps://orcid.org/0000-0002-7838-1005LushnikovaA. A.ЛушниковаА. А.
Russian Federation
LAN21@yandex.ruhttps://orcid.org/0000-0001-8040-5929KostarevA. V.КостаревА. В.
Russian Federation
https://orcid.org/0000-0002-1624-7556PonkratovaD. A.ПонкратоваД. А.
Russian Federation
https://orcid.org/0000-0003-0217-2685OnyanA. V.ОнянА. В.
Russian Federation
https://orcid.org/0000-0002-1206-287XGlubokovaE. G.ГлубоковаЕ. Г.
Russian Federation
https://orcid.org/0000-0001-8297-579XAndreevS. M.АндреевС. М.
Russian Federation
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии Н.Н. Блохина» Минздрава РоссииM.V. Lomonosov Moscow State UniversityФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»Immunology Institute, Federal Medical and Biological Agency of RussiaФГБУ «ГНЦ Институт иммунологии» ФМБА России150920185359641011201810112018Copyright ©; 2018, Lushnikova A.A., Kostarev A.V., Ponkratova D.A., Onyan A.V., Glubokova E.G., Andreev S.M.Copyright ©; 2018, Лушникова А.А., Костарев А.В., Понкратова Д.А., Онян А.В., Глубокова Е.Г., Андреев С.М.2018Lushnikova A.A., Kostarev A.V., Ponkratova D.A., Onyan A.V., Glubokova E.G., Andreev S.M.Лушникова А.А., Костарев А.В., Понкратова Д.А., Онян А.В., Глубокова Е.Г., Андреев С.М.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/166

Background. Chaperone proteins nucleolin (NCL, or C23) and nucleophosmin (NPM, or B23) regulate key cell functions. The most tumors are characterized by over-expression of these proteins, especially in cell nuclei and on the сell surface, as NCL. Differential expression of NCL/NPM in tumor and normal cells is the basis of selective cytotoxicity of cationic peptides – expected ligands for these proteins. Objective. Analysis of the interactions between nucleolin and some peptides with high nonspecific toxicity for tumor cells. Materials and methods. The interaction of 4 previously characterized cationic peptides with nucleolin dimer was analyzed by pair molecular docking using Maestro 11 program. Results and conclusion. It is shown that these peptides can associate with receptor nucleolin molecules, forming energy-stable complexes. In the active centre of NCL molecule were found, at least, 7 positions of amino acids, which bind to the tested peptides at a high frequency (43–100 %). This indicates the conservative structure of dimer NCL, its stable binding to peptide ligands and the possibility of design the optimal structure of cationic peptides that induce tumor cell death due to competing binding to the target proteins.

malignant tumornucleolincationic peptidemolecular dockingзлокачественная опухольнуклеолинкатионные пептидымолекулярный докингThe study was performed with state financial support (project No 144112440122).Исследование проведено с поддержкой по бюджетному финансированию (№ проекта ГЗ 144112440122)1. Fujiki H., Watanabe T., Suganuma M. Cell-sufaсe nucleolin acts as a central mediator for carcinogenic, anti-carcinogenic, and disease-related ligands. J Cancer Res Clin Oncol 2014;140(7):689–99. DOI: 10.1007/s00432-014-1587-5. PMID: 24469254.Fujiki H., Watanabe T., Suganuma M. Cell-sufaсe nucleolin acts as a central mediator for carcinogenic, anti-carcinogenic, and disease-related ligands. J Cancer Res Clin Oncol 2014;140(7):689–99. DOI: 10.1007/s00432-014-1587-5. PMID: 24469254.2. Koutsioumpa M., Papadimitriou E. Cellsuface nucleolin as a target for anti-cancer therapies. Recent Part Anticancer Drug Discov 2018;9(2):137–52. PMID: 24251811.Koutsioumpa M., Papadimitriou E. Cellsuface nucleolin as a target for anti-cancer therapies. Recent Part Anticancer Drug Discov 2018;9(2):137–52. PMID: 24251811.3. Lushnikova A., Ponkratova D., Andreev S. et al. A рossibility for therapy of metastatic cutaneous melanoma with cationic peptides. Eur J Cancer 2017;72(Sl): 127–28.Lushnikova A., Ponkratova D., Andreev S. et al. A рossibility for therapy of metastatic cutaneous melanoma with cationic peptides. Eur J Cancer 2017;72(Sl): 127–28.4. Lushnikova A.A., Ponkratova D.A., Rudakova A.A. et al. The mechanisms of antitumor toxicity in a number of cationic peptides. Modern Science 2017;11:124–6.Lushnikova A.A., Ponkratova D.A., Rudakova A.A. et al. The mechanisms of antitumor toxicity in a number of cationic peptides. Modern Science 2017;11:124–6.5. Lushnikova A.A., Ponkratova D.A., Morozova L.F., Andreev S.M. Induction of apoptosis in cutaneous melanoma cells by cationic peptides. Int Sci J 2017;7– 2(61):75–9.Lushnikova A.A., Ponkratova D.A., Morozova L.F., Andreev S.M. Induction of apoptosis in cutaneous melanoma cells by cationic peptides. Int Sci J 2017;7– 2(61):75–9.6. Dang W., Muto Y., Inoue Y. et al. RCSB PDB TI Solution structure of the RRM_1domain of NCL protein. FAUCRDT 2005;12(12). Available at: http://www.rcsb.org/structure/2FC8.Dang W., Muto Y., Inoue Y. et al. RCSB PDB TI Solution structure of the RRM_1domain of NCL protein. FAUCRDT 2005;12(12). Available at: http://www.rcsb.org/structure/2FC8.7. Kellenberger E., Rodrigo J., Muller P., Rognan D. Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins 2004;57(2):225–42. DOI: 10.1002/prot. 20149. PMID: 15340911.Kellenberger E., Rodrigo J., Muller P., Rognan D. Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins 2004;57(2):225–42. DOI: 10.1002/prot. 20149. PMID: 15340911.8. Site Map User Manual. Schrödinger: LLC. Schrödinger Press, 2009.Site Map User Manual. Schrödinger: LLC. Schrödinger Press, 2009.9. Glide User Manual. Schrödinger: LLC. Schrödinger Press, 2015.Glide User Manual. Schrödinger: LLC. Schrödinger Press, 2015.10. Induced Fit Docking. Schrödinger: LLC. Schrödinger Press, 2009.Induced Fit Docking. Schrödinger: LLC. Schrödinger Press, 2009.11. Du X., Li Y., Xia Y.L. et al. Insights into protein-ligand interactions: mechanisms, models, and methods. Int J Mol Sci 2016;17(2):144–78. DOI: 10.3390/ijms17020144. PMID: 26821017.Du X., Li Y., Xia Y.L. et al. Insights into protein-ligand interactions: mechanisms, models, and methods. Int J Mol Sci 2016;17(2):144–78. DOI: 10.3390/ijms17020144. PMID: 26821017.12. Balça-Silva J., do Carmo A., Täo H. et al. Nucleolin is expressed in patient-derived samples and glioblastoma cells, enabling improved intracellular drug delivery and cytotoxicity. Exp Cell Res 2018;370(1): 68–77. DOI: 10.1016/j.yexcr.2018.06.005. PMID: 29902537.Balça-Silva J., do Carmo A., Täo H. et al. Nucleolin is expressed in patient-derived samples and glioblastoma cells, enabling improved intracellular drug delivery and cytotoxicity. Exp Cell Res 2018;370(1): 68–77. DOI: 10.1016/j.yexcr.2018.06.005. PMID: 29902537.